Iovance Biotherapeutics, Inc. - Common Stock (IOVA)

Tread carefully, but certain factors make this speculative biotech play stand out.

Oncotelic Therapeutics (OTCQB: OTLC) is advancing its Sapu003 program and Deciparticle platform as part of a strategy focused on improving the delivery, bioavailability and therapeutic consistency of oncology treatments. As biotechnology companies increasingly explore ways to enhance the performance of existing therapies rather than developing entirely new compounds, Oncotelic is leveraging nanotechnology-enabled drug-delivery systems and pharmacokinetic optimization to potentially improve therapeutic outcomes while reducing development risk. The company’s approach aligns with broader industry trends favoring advanced delivery technologies that may offer faster development timelines and expanded commercial opportunities.

BioMedWire Editorial Coverage: As oncology drug-development costs continue climbing and regulatory pathways become increasingly complex, biotechnology companies are placing renewed emphasis on improving existing therapeutics through advanced delivery technologies rather than relying exclusively on discovering entirely new drugs. Across the healthcare sector, growing attention is being directed toward nanoparticle delivery systems, intravenous reformulations and precision pharmacokinetic strategies designed to potentially improve bioavailability, systemic exposure, tolerability and dosing consistency of established cancer therapies. Within this broader movement, Oncotelic Therapeutics Inc. (OTCQB: OTLC) ( Profile ) is advancing its Sapu003 program and Deciparticle(TM) platform as part of a larger industry trend focused on scalable nanotechnology-enabled drug delivery and AI-enhanced biomedical infrastructure. The company’s strategy centers on leveraging platform technologies that may support multiple therapeutic applications across oncology and rare disease markets rather than relying solely on a single drug candidate. Oncotelic is one of several companies, including Northwest Biotherapeutics Inc. (OTCQB: NWBO), Sangamo Therapeutics Inc. (OTCQB: SGMO), HIVE Digital Technologies Ltd. (NASDAQ: HIVE) and Iovance Biotherapeutics Inc. (NASDAQ: IOVA), that are building scalable platforms — whether cancer immunotherapy, genomic medicine, AI/data infrastructure or cell therapy — rather than…

AUSTIN, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: As oncology drug-development costs continue climbing and regulatory pathways become increasingly complex, biotechnology companies are placing renewed emphasis on improving existing therapeutics through advanced delivery technologies rather than relying exclusively on discovering entirely new drugs. Across the healthcare sector, growing attention is being directed toward nanoparticle delivery systems, intravenous reformulations and precision pharmacokinetic strategies designed to potentially improve bioavailability, systemic exposure, tolerability and dosing consistency of established cancer therapies. Within this broader movement, Oncotelic Therapeutics Inc. (OTCQB: OTLC) (profile) is advancing its Sapu003 program and Deciparticle(TM) platform as part of a larger industry trend focused on scalable nanotechnology-enabled drug delivery and AI-enhanced biomedical infrastructure. The company’s strategy centers on leveraging platform technologies that may support multiple therapeutic applications across oncology and rare disease markets rather than relying solely on a single drug candidate. Oncotelic is one of several companies, including Northwest Biotherapeutics Inc. (OTCQB: NWBO), Sangamo Therapeutics Inc. (OTCQB: SGMO), HIVE Digital Technologies Ltd. (NASDAQ: HIVE) and Iovance Biotherapeutics Inc. (NASDAQ: IOVA), that are building scalable platforms — whether cancer immunotherapy, genomic medicine, AI/data infrastructure or cell therapy — rather than single-product biotechnology stories alone.

Next-Generation Platform Expands into Solid Tumors Representing 100,000+ U.S. Deaths Annually

SAN CARLOS, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on May 21, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 93,340 shares of Iovance’s common stock to thirteen new, non-executive employees.

SAN CARLOS, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that Fred Vogt, PhD, Interim CEO, President and General Counsel, and Corleen Roche, Chief Financial Officer, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 1:25 p.m. ET in New York, NY.

Iovance (IOVA) Q1 2026 Earnings Transcript

1Q26 Total Revenue of ~$71M Delivers ~45% Year-over-Year Growth

It could just as well drop by 50% -- or more -- over the next 12 months.

SAN CARLOS, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast on Thursday, May 7, 2026 at 8:30 a.m. ET to report its first quarter 2026 financial results and corporate updates.

This oncology specialist has proven innovative abilities.

SAN CARLOS, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on March 19, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 3,400 shares of Iovance’s common stock to one new, non-executive employee.

If you decide to invest in this company, it's probably best to start small.

Investors are increasingly comparing ImmunityBio and Iovance Biotherapeutics as both cancer drug developers move into catalyst-heavy phases.

SAN CARLOS, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following upcoming conferences:

Chardan cited operational efficiencies and expected margin lift as Lifileucel manufacturing is fully internalized.

Iovance (IOVA) Q4 2025 Earnings Call Transcript

The company announced encouraging early results from a pilot study evaluating its tumor-infiltrating lymphocyte therapy, lifileucel and reported strong fourth-quarter earnings.

~30% Quarterly Revenue Growth Driven by Amtagvi Demand